30.05.2013 - Danish Novo A/S has secured royalties on an upcoming competitor treatment to the age-related macular degeneration drug Lucentis.
In total, the Danish injected US$175m to push Phase III development of Ophtotec’s AMD drug Fovista (E10030). The company led a US$50m Series C financing and secured a share on future royalties with the anti-PDGF pegylated aptamer in exchange for US$125m.
In Phase IIb studies, dosing 449 patients with wet AMD with 6 monthly injections of Fovista plus Lucentis in the eye led to an 62% improvement of vision compared to Lucentis monotherapy after 6 months. Last year Roche’s VEGF-targeting angiogenesis blocker, which is distributed in Europe by Novartis, made more that 1.5bn in sales.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more